Inspira Technologies Oxy B.H.N. Ltd. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
IINN Nasdaq 3840 inspira-technologies.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Inspira Technologies Oxy B.H.N. Ltd.

Inspira Secures Vendor Approval from $12 Billion Revenue HMO (World’s 2nd Largest), Enabling Immediate ART100 Deployment - Feb 9th, 2026 5:00 am
Inspira Announces Pricing of $4.75 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules - Feb 5th, 2026 6:00 am
Inspira Technologies Validates Next-Gen Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy, Targeting $48 Billion Heart-Lung Surgery Market - Feb 3rd, 2026 7:22 am
ART100 Becomes Inspira’s First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center - Jan 29th, 2026 6:30 am
Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders - Jan 21st, 2026 6:50 am
Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion - Jan 8th, 2026 6:50 am
CORRECTION – Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation - Jan 5th, 2026 8:46 am
Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation - Jan 5th, 2026 7:30 am
Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones - Dec 23rd, 2025 6:30 am
Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution - Dec 15th, 2025 6:30 am
Inspira Technologies Granted Patent in Japan for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use - Dec 9th, 2025 6:05 am
Inspira Technologies Announces Strategic Leap in Lab Capabilities – Accelerating Next-Generation Diagnostics and Blood Technology - Dec 3rd, 2025 6:43 am
Inspira Completes Clinical Study for HYLA™ Blood Sensor - Ahead of Regulatory Submission - Nov 13th, 2025 7:00 am
Inspira Technologies Nears Final Regulatory Clearance for the ART100 in the UAE, Accelerating Gulf Region Expansion - Nov 6th, 2025 7:10 am
Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira’s Global Ecosystem - Oct 22nd, 2025 6:30 am
Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm - Oct 21st, 2025 1:40 pm
Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm - Oct 21st, 2025 7:05 am
Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update - Oct 1st, 2025 6:00 am
All You Need to Know About Inspira Technologies OXY (IINN) Rating Upgrade to Buy - Sep 22nd, 2025 10:00 am
Inspira to Unveil HYLA™ Real-Time Blood Sensor at U.S. ELSO; 97.35% Accuracy Confirmed - Sep 18th, 2025 6:00 am